340 related articles for article (PubMed ID: 17047192)
21. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ
Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596
[TBL] [Abstract][Full Text] [Related]
22. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
23. Small-molecular modulators of cancer-associated epigenetic mechanisms.
Itoh Y; Suzuki T; Miyata N
Mol Biosyst; 2013 May; 9(5):873-96. PubMed ID: 23511667
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.
Yamamoto M; Ito T; Shimizu T; Ishida T; Semba K; Watanabe S; Yamaguchi N; Inoue J
Cancer Sci; 2010 Nov; 101(11):2391-7. PubMed ID: 20735436
[TBL] [Abstract][Full Text] [Related]
25. Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.
Huisman C; van der Wijst MG; Falahi F; Overkamp J; Karsten G; Terpstra MM; Kok K; van der Zee AG; Schuuring E; Wisman GB; Rots MG
Epigenetics; 2015; 10(5):384-96. PubMed ID: 25830725
[TBL] [Abstract][Full Text] [Related]
26. Development of curcumin as an epigenetic agent.
Fu S; Kurzrock R
Cancer; 2010 Oct; 116(20):4670-6. PubMed ID: 20597137
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic transitions: towards therapeutic targets.
Kalebic T
Expert Opin Ther Targets; 2003 Dec; 7(6):693-9. PubMed ID: 14640906
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic characteristics and development of embryos cloned from donor cells treated by trichostatin A or 5-aza-2'-deoxycytidine.
Enright BP; Kubota C; Yang X; Tian XC
Biol Reprod; 2003 Sep; 69(3):896-901. PubMed ID: 12748129
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic agents in combined anticancer therapy.
Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
31. Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells.
Jugová A; Sustáčková G; Legartová S; Stixová L; Kozubek S; Bártová E
Cell Biol Int; 2011 Dec; 35(12):1195-203. PubMed ID: 21635225
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
33. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic drug discovery: targeting DNA methyltransferases.
Foulks JM; Parnell KM; Nix RN; Chau S; Swierczek K; Saunders M; Wright K; Hendrickson TF; Ho KK; McCullar MV; Kanner SB
J Biomol Screen; 2012 Jan; 17(1):2-17. PubMed ID: 21965114
[TBL] [Abstract][Full Text] [Related]
35. Epigenetics meets immune checkpoints.
Covre A; Coral S; Di Giacomo AM; Taverna P; Azab M; Maio M
Semin Oncol; 2015 Jun; 42(3):506-13. PubMed ID: 25965370
[TBL] [Abstract][Full Text] [Related]
36. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
Kim B; Rincón Castro LM; Jawed S; Niles LP
Eur J Pharmacol; 2008 Jul; 589(1-3):45-8. PubMed ID: 18550052
[TBL] [Abstract][Full Text] [Related]
37. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
38. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
40. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
